6.99
-0.05(-0.71%)
Currency In USD
| Previous Close | 7.04 |
| Open | 7.09 |
| Day High | 7.1 |
| Day Low | 6.94 |
| 52-Week High | 8.24 |
| 52-Week Low | 4.63 |
| Volume | 17,808 |
| Average Volume | 79,206 |
| Market Cap | 31.89M |
| PE | 2.38 |
| EPS | 2.94 |
| Moving Average 50 Days | 6.93 |
| Moving Average 200 Days | 6.25 |
| Change | -0.05 |
If you invested $1000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, it would be worth $0.07 as of November 13, 2025 at a share price of $6.99. Whereas If you bought $1000 worth of Tenax Therapeutics, Inc. (TENX) shares 5 years ago, it would be worth $4.04 as of November 13, 2025 at a share price of $6.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 03, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
GlobeNewswire Inc.
Sep 16, 2025 11:00 AM GMT
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimen